Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by progressive loss of dopaminergic neurons that results in characteristic motor and non-motor symptoms. l-3,4 dihydroxyphenylalanine (l-DOPA) is the gold standard therapy for the treatment of PD. However, l...

Descripción completa

Detalles Bibliográficos
Autores principales: Tóth, Adrián, Antal, Zsófia, Bereczki, Dániel, Sperlágh, Beáta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776560/
https://www.ncbi.nlm.nih.gov/pubmed/31054067
http://dx.doi.org/10.1007/s11064-019-02798-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776560/
https://www.ncbi.nlm.nih.gov/pubmed/31054067
http://dx.doi.org/10.1007/s11064-019-02798-1

Ejemplares similares